Study of Adalimumab (HUMIRA®) in Patients With Moderate to Severe Psoriasis (PS) in Spain (PROMISE)

Study Identifier
P11-067
CT.gov Identifier
NCT01076192
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Results Available

Scientific Result Summary
Available Language(s): English
Download document(s)

Study Details

Medical Condition
  • Dermatology - Psoriasis (PsO)
    • Study Drug
    N/A
    Phase
    N/A
    Sex
    Female & Male
    Age
    18+ years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    * Patient 18 years of age or older. * Patient diagnosed with moderate to severe chronic plaque PS beginning treatment with adalimumab in accordance with the authorized conditions of use. * Patient gives informed consent in writing.
    Exclusion Criteria:
    * Patients who cannot be treated in accordance with the local product label * Patient participating or going to participate in a clinical trial during the study follow-up * Patient with difficulties for adequately reading, understanding and completing a questionnaire

    Protocol Summary

    The purpose of this study is to evaluate the effectiveness and safety of adalimumab as used in routine clinical practice in adult patients with moderate to severe chronic plaque psoriasis in Spain.

    Study Locations

    No locations found.